SMARCB1 Gene Therapy Using a Novel Tumor-Targeted Nanomedicine Enhances Anti-Cancer Efficacy in a Mouse Model of Atypical Teratoid Rhabdoid Tumors

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Lau CS, Mahendraraj K, Chamberlain RS. Atypical teratoid rhabdoid tumors: a population-based clinical outcomes study involving 174 patients from the Surveillance, Epidemiology, and End Results database (1973-2010). Cancer Manag Res. 2015;7:301–309.
   PubMed Web of Science ®Google Scholar
• Ginn KF, Gajjar A. Atypical teratoid rhabdoid tumor: current therapy and future directions. Front Oncol. 2012;2:114.
   PubMedGoogle Scholar
• Lafay-Cousin L, Hawkins C, Carret AS, et al. Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience. Eur J Cancer. 2012;48(3):353–359.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Douglass EC, Valentine M, Rowe ST, et al. Malignant rhabdoid tumor: a highly malignant childhood tumor with minimal karyotypic changes. Genes Chromosomes Cancer. 1990;2(3):210–216.
   PubMed Web of Science ®Google Scholar
• Hasselblatt M, Isken S, Linge A, et al. High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes Cancer. 2013;52(2):185–190.
   PubMed Web of Science ®Google Scholar
• Lee RS, Stewart C, Carter SL, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012;122(8):2983–2988.
   PubMed Web of Science ®Google Scholar
• Alimova I, Pierce A, Danis E, et al. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo. Int j Cancer. 2019;144(8):1983–1995.
   PubMed Web of Science ®Google Scholar
• Buscariollo DL, Park HS, Roberts KB, Yu JB. Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer. 2012;118(17):4212–4219.
   PubMed Web of Science ®Google Scholar
• Biegel JA, Tan L, Zhang F, Wainwright L, Russo P, Rorke LB. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clini Cancer Res. 2002;8(11):3461–3467.
   PubMed Web of Science ®Google Scholar
• Mathur R, Roberts CWM. SWI/SNF (BAF) Complexes: guardians of the Epigenome. Annu Rev Canc Biol. 2018;2:413–427.
   Google Scholar
• Biegel JA, Allen CS, Kawasaki K, Shimizu N, Budarf ML, Bell CJ. Narrowing the critical region for a rhabdoid tumor locus in 22q11. Genes Chromosomes Cancer. 1996;16(2):94–105.
   PubMed Web of Science ®Google Scholar
• Torchia J, Golbourn B, Feng S, et al. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell. 2016;30(6):891–908.
   PubMed Web of Science ®Google Scholar
• Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394:6689.
   Web of Science ®Google Scholar
• Chasse MH, Johnson BK, Boguslawski EA, et al. Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor. EMBO Mol. Med. 2021;13(2).
   PubMed Web of Science ®Google Scholar
• Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene. 2002;21(34):5193–5203.
   PubMed Web of Science ®Google Scholar
• Isakoff MS, Sansam CG, Tamayo P, et al. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci U S A. 2005;102(49):17745–17750.
   PubMed Web of Science ®Google Scholar
• Lee D, Kim JW, Seo T, Hwang SG, Choi EJ, Choe J. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J Biol Chem. 2002;277(25):22330–22337.
   PubMed Web of Science ®Google Scholar
• Lee S, Cimica V, Ramachandra N, Zagzag D, Kalpana GV. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival. Cancer Res. 2011;71(9):3225–3235.
   PubMed Web of Science ®Google Scholar
• Oruetxebarria I, Venturini F, Kekarainen T, et al. P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. J Biol Chem. 2004;279(5):3807–3816.
   PubMed Web of Science ®Google Scholar
• Versteege I, Medjkane S, Rouillard D, Delattre O. A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle. Oncogene. 2002;21(42):6403–6412.
   PubMed Web of Science ®Google Scholar
• Fruhwald MC, Biegel JA, Bourdeaut F, Roberts CW, Chi SN. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. Neuro-Oncology. 2016;18(6):764–778.
   PubMed Web of Science ®Google Scholar
• Lee YE, Choi SA, Kwack PA, et al. Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor. Neuro-Oncology. 2017;19(8):1079–1087.
   PubMed Web of Science ®Google Scholar
• Xu L, Huang CC, Huang W, et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther. 2002;1(5):337–346.
   PubMed Web of Science ®Google Scholar
• Kim SS, Rait A, Kim E, et al. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS nano. 2014;8(6):5494–5514.
   PubMed Web of Science ®Google Scholar
• Kim SS, Harford JB, Pirollo KF, Chang EH. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: the promise of nanomedicine. Biochem Biophys Res Commun. 2015;468(3):485–489.
   PubMed Web of Science ®Google Scholar
• Kim SS, Rait A, Kim E, DeMarco J, Pirollo KF, Chang EH. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Cancer Lett. 2015;369(1):250–258.
   PubMed Web of Science ®Google Scholar
• Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther. 1999;10(18):2941–2952.
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodriguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820(3):291–317.
   PubMed Web of Science ®Google Scholar
• Prior R, Reifenberger G, Wechsler W. Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction. Virchows Arch a Pathol Anat Histopathol. 1990;416(6):491–496.
   PubMedGoogle Scholar
• Xu L, Tang WH, Huang CC, et al. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med. 2001;7(10):723–734.
   PubMed Web of Science ®Google Scholar
• Kim SS, Rait A, Rubab F, et al. The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells. Mol Ther. 2014;22(2):278–291.
   PubMed Web of Science ®Google Scholar
• GeneCards: The Human Gene Database [homepage on the Internet]. Rehovot, Israel: Weizmann Institute of Science; 2024. Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=SMARCB1. Accessed May 20, 2024.
   Google Scholar
• Morozov A, Lee SJ, Zhang ZK, Cimica V, Zagzag D, Kalpana GV. INI1 induces interferon signaling and spindle checkpoint in rhabdoid tumors. Clini Cancer Res. 2007;13(16):4721–4730.
   PubMed Web of Science ®Google Scholar
• Venkataraman S, Alimova I, Tello T, et al. Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells. J Neurooncol. 2012;107(3):517–526.
   PubMed Web of Science ®Google Scholar
• Major K, Daggubati LC, Mau C, Zacharia B, Glantz M, Pu C. Sellar Atypical Teratoid/Rhabdoid Tumors (AT/RT): a Systematic Review and Case Illustration. Cureus. 2022;14(7).
   Web of Science ®Google Scholar
• Das SK, Menezes ME, Bhatia S, et al. Gene Therapies for Cancer: strategies, Challenges and Successes. J Cell Physiol. 2015;230(2):259–271.
   PubMed Web of Science ®Google Scholar
• van Haasteren J, Li J, Scheideler OJ, Murthy N, Schaffer DV. The delivery challenge: fulfilling the promise of therapeutic genome editing. Nat Biotechnol. 2020;38(7):845–855.
   PubMed Web of Science ®Google Scholar
• Hoffman LM, Richardson EA, Ho B, et al. Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. Neuro-Oncology. 2020;22(7):944–954.
   PubMed Web of Science ®Google Scholar
• Richardson EA, Ho B, Huang A. Atypical Teratoid Rhabdoid Tumour: from Tumours to Therapies. J Korean Neurosurg Soc. 2018;61(3):302–311.
   PubMed Web of Science ®Google Scholar
• Thakur S, Ruan Y, Zhang C, Lun X, Jayanthan A, Narendran A. Human SNF5 arming of double-deleted vaccinia virus shows oncolytic and cytostatic activity against central nervous system atypical teratoid/rhabdoid tumor cells. Cancer Gene Ther. 2021;28(7–8).
   PubMed Web of Science ®Google Scholar
• Pulgar VM. Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges. Front Neurosci. 2018;12:1019.
   PubMed Web of Science ®Google Scholar
• Kim SS, Rait A, Garrido-Sanabria ER, Pirollo KF, Harford JB, Chang EH. Nanotherapeutics for Gene Modulation that Prevents Apoptosis in the Brain and Fatal Neuroinflammation. Mol Ther. 2018;26(1):84–94.
   PubMed Web of Science ®Google Scholar
• Kohashi K, Oda Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci. 2017;108(4):547–552.
   PubMed Web of Science ®Google Scholar
• Upadhyaya SA, Campagne O, Billups CA, et al. Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. Neuro-Oncology. 2023;25(2):386–397.
   PubMed Web of Science ®Google Scholar
• Ho B, Johann PD, Grabovska Y, et al. Molecular subgrouping of atypical teratoid/rhabdoid tumors-A reinvestigation and current consensus. Neuro-Oncology. 2020;22(5):613–624.
   PubMed Web of Science ®Google Scholar
• Johann PD, Erkek S, Zapatka M, et al. Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell. 2016;29(3):379–393.
   PubMed Web of Science ®Google Scholar
• Stojanova A, Tu WB, Ponzielli R, et al. MYC interaction with the tumor suppressive SWI/SNF complex member INI1 regulates transcription and cellular transformation. Cell Cycle. 2016;15(13):1693–1705.
   PubMed Web of Science ®Google Scholar
• Weissmiller AM, Wang J, Lorey SL, et al. Inhibition of MYC by the SMARCB1 tumor suppressor. Nat Commun. 2019;10(1):2014.
   PubMed Web of Science ®Google Scholar
• Algar EM, Muscat A, Dagar V, et al. Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. PLoS One. 2009;4(2).
   PubMed Web of Science ®Google Scholar
• Marhin WW, Chen S, Facchini LM, Fornace AJ, Penn LZ. Myc represses the growth arrest gene gadd45. Oncogene. 1997;14(23):2825–2834.
   PubMed Web of Science ®Google Scholar
• Shao S, Wang Y, Jin S, et al. Gadd45a interacts with Aurora-A and inhibits its kinase activity. J Biol Chem. 2006;281(39):28943–28950.
   PubMed Web of Science ®Google Scholar
• Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993;328(24):1725–1731.
   PubMed Web of Science ®Google Scholar
• Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 2005;6(8):573–580.
   PubMed Web of Science ®Google Scholar
• Senzer N, Nemunaitis J, Nemunaitis D, et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther. 2013;21(5):1096–1103.
   PubMed Web of Science ®Google Scholar
• Siefker-Radtke A, Zhang XQ, Guo CC, et al. A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. Mol Ther. 2016;24(8):1484–1491.
   PubMed Web of Science ®Google Scholar
• Sehdev V, Peng D, Soutto M, et al. The Aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther. 2012;11(3):763–774.
   PubMed Web of Science ®Google Scholar
• Vlachos P, Nyman U, Hajji N, Joseph B. The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway. Cell Death Differ. 2007;14(8):1497–1507.
   PubMed Web of Science ®Google Scholar